The neoadjuvant model is still the future for drug development in breast cancer

Angela De Michele, Douglas Yee, Donald A. Berry, Kathy S. Albain, Christopher C. Benz, Judy Boughey, Meredith Buxton, Stephen K. Chia, Amy J. Chien, Stephen Y. Chui, Amy Clark, Kirsten Edmiston, Anthony D. Elias, Andres Forero-Torres, Tufia C. Haddad, Barbara Haley, Paul Haluska, Nola M. Hylton, Claudine Isaacs, Henry KaplanLarissa Korde, Brian Leyland-Jones, Minetta C. Liu, Michelle Melisko, Susan E. Minton, Stacy L. Moulder, Rita Nanda, Olufunmilayo I. Olopade, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Emanuel F. Petricoin, Hope Rugo, Fraser Symmans, Debasish Tripathy, Laura J. Van't Veer, Rebecca K. Viscusi, Anne Wallace, Denise Wolf, Christina Yau, Laura J. Esserman

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Fingerprint Dive into the research topics of 'The neoadjuvant model is still the future for drug development in breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences